These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6166805)

  • 1. Hemodynamic profile of a new antihypertensive agent D,L-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine (SK&F 92657).
    Taylor EM; Cameron D; Eden RJ; Fielden R; Owen DA
    J Cardiovasc Pharmacol; 1981; 3(2):337-54. PubMed ID: 6166805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SK&F 92657, a novel antihypertensive acting by precapillary vasodilatation and beta-adrenoreceptor blockade.
    Taylor EM; Roe AM; Slater RA
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():433s-436s. PubMed ID: 44235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the autonomic nervous system with SK&F 92657, a new antihypertensive agent causing direct arterial vasodilatation and beta-adrenoceptor blockade.
    Taylor EM; Eden RJ; Fielden R; Owen DA
    J Cardiovasc Pharmacol; 1981; 3(2):355-68. PubMed ID: 6166806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacological studies with SK&F 94836, a potent inotrope/vasodilator with a sustained duration of action.
    Gristwood RW; Comer MB; Eden RJ; Taylor EM; Turner JA; Wallduck M; Owen DA
    Br J Pharmacol; 1988 Apr; 93(4):893-901. PubMed ID: 3390657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypotensive and vasodilator actions of SK&F 24260, a new dihydropyridine derivative.
    Fielden R; Owen DA; Taylor EM
    Br J Pharmacol; 1974 Nov; 52(3):323-32. PubMed ID: 4458842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SK & F 95018, a vasodilator/beta-adrenoceptor antagonist.
    Swayne GT; Owen DA; Taylor EM; Eden RJ; Slater RA; Howson W
    Arch Int Pharmacodyn Ther; 1987 Oct; 289(2):251-66. PubMed ID: 2892473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanism of the acute antihypertensive and vasodilator actions of several beta-adrenoceptor antagonists.
    Sybertz EJ; Baum T; Pula KK; Nelson S; Eynon E; Sabin C
    J Cardiovasc Pharmacol; 1982; 4(5):749-58. PubMed ID: 6182405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.
    Brooks DP; Fredrickson TA; Weinstock J; Ruffolo RR; Edwards RM; Gellai M
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jun; 345(6):673-8. PubMed ID: 1635591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs.
    Dorigotti L; Ferni G; Lombroso M; Semeraro C
    Arzneimittelforschung; 1984; 34(9):984-7. PubMed ID: 6542375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary and systemic hemodynamic effects of the putative nitric oxide donor, FK 409, in comparison with nitroglycerin in conscious and anesthetized dogs.
    Drieu la Rochelle C; Lainée P; Grosset A; O'Connor SE
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):555-63. PubMed ID: 8569215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator.
    Baldoli E; Bianchi G; Corsico N; Di Francesco GF
    Arzneimittelforschung; 1985; 35(5):818-26. PubMed ID: 2862874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of a novel vasoactive antihypertensive agent, Ro 12-4713.
    Gerold M; Eigenmann R; Hefti F; Daum A; Haeusler G
    J Pharmacol Exp Ther; 1981 Mar; 216(3):624-33. PubMed ID: 7009831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs.
    Salzmann R; Gerber W; Pally C; Scholtysik G
    J Pharm Pharmacol; 1983 May; 35(5):293-8. PubMed ID: 6134797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiohemodynamic effects of SK&F 24260, D 600, diltiazem, dilazep, and trimetazidine in the dog.
    Imai Y; Himori N; Taira N
    Jpn Heart J; 1977 Jan; 18(1):120-31. PubMed ID: 846043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.
    Kinter LB; Horner E; Mann WA; Weinstock J; Ruffolo RR
    Chirality; 1990; 2(4):219-25. PubMed ID: 1982058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic and coronary hemodynamic effects of pinacidil in awake normotensive and hypertensive dogs.
    Kawashima S; Liang CS
    Hypertension; 1985; 7(4):525-32. PubMed ID: 3891613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and pharmacokinetic studies on prizidilol and nipradilol (K-351), antihypertensive drugs with combined vasodilator and beta-adrenoceptor blocking actions, in rabbits.
    Kawashima K; Watanabe TX; Sokabe H
    Jpn J Pharmacol; 1984 Dec; 36(4):519-26. PubMed ID: 6151998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic profile of N-(2,5-dimethyl-1H-pyrrol-1-yl)6-(4-morpholinyl)-3-pyridazinamine hydrochloride in conscious dogs.
    Di Francesco GF; Baldoli E; Marchetti G; Glässer A
    Arzneimittelforschung; 1986; 36(1):84-8. PubMed ID: 3954821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist.
    Lee BH; Seo HW; Kwon KJ; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):375-82. PubMed ID: 10069671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular pharmacology of nicardipine in animals.
    Takenaka T; Asano M; Shiono K; Shibasaki M; Inagaki O
    Br J Clin Pharmacol; 1985; 20 Suppl 1(Suppl 1):7S-22S. PubMed ID: 4027153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.